PMID- 37459281
OWN - NLM
STAT- MEDLINE
DCOM- 20230831
LR  - 20230902
IS  - 1473-6322 (Electronic)
IS  - 1473-6322 (Linking)
VI  - 23
IP  - 5
DP  - 2023 Oct 1
TI  - Chronic spontaneous urticaria: new evidences on the role of autoimmunity.
PG  - 438-445
LID - 10.1097/ACI.0000000000000927 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to provide an overview of the 
      recent advancements and relevance of the autoimmune theories in chronic 
      spontaneous urticaria (CSU). RECENT FINDINGS: Two primary types of autoimmunity, 
      Type I and Type IIb, have emerged as major contributors to CSU, characterized by 
      immunoglobulin E (IgE) and immunoglobulin G (IgG) autoantibodies, respectively. 
      Genetic evidence supports the notion that CSU shares more similarities with other 
      autoimmune diseases rather than atopic diseases. Novel autoallergens such as 
      FcepsilonRI and tissue transglutaminase have been identified, contributed to our 
      understanding of autoimmune mechanisms. Furthermore, the potential overlap 
      between Type I and Type IIb autoimmunity has been recognized. Evaluating the 
      autoimmune status of CSU patients through biomarkers and understanding their 
      clinical implications is vital for effective management. For instance, CSU 
      patients with Type IIb autoimmunity, with or without coexisting Type I 
      autoimmunity, may exhibit resistance to H1-antihistamines and omalizumab 
      treatment but could potentially respond well to cyclosporine or Bruton's tyrosine 
      kinase inhibitors. SUMMARY: Further investigations are needed to explore new 
      autoallergens and autoantibodies in CSU, establishing their connection to the 
      development of autoimmunity. The efficacy of novel drugs targeting different 
      mechanisms should be examined to determine their responses in both autoimmune CSU 
      and nonautoimmunity-related CSU.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Xiang, Yi-Kui
AU  - Xiang YK
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 
      Allergology and Immunology, Berlin, Germany.
FAU - Guloglu, Sercan
AU  - Guloglu S
AD  - Koc University, Graduate School of Health Sciences, Immunology.
FAU - Elieh-Ali-Komi, Daniel
AU  - Elieh-Ali-Komi D
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 
      Allergology and Immunology, Berlin, Germany.
FAU - Kocaturk, Emek
AU  - Kocaturk E
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 
      Allergology and Immunology, Berlin, Germany.
AD  - Koc University, School of Medicine, Department of Dermatology, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230706
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
RN  - 0 (Autoantibodies)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Humans
MH  - Autoimmunity
MH  - *Urticaria
MH  - Chronic Disease
MH  - *Chronic Urticaria
MH  - *Autoimmune Diseases
MH  - Autoantibodies/therapeutic use
MH  - Omalizumab/therapeutic use
EDAT- 2023/07/17 15:09
MHDA- 2023/08/31 06:41
CRDT- 2023/07/17 13:03
PHST- 2023/08/31 06:41 [medline]
PHST- 2023/07/17 15:09 [pubmed]
PHST- 2023/07/17 13:03 [entrez]
AID - 00130832-990000000-00072 [pii]
AID - 10.1097/ACI.0000000000000927 [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):438-445. doi: 
      10.1097/ACI.0000000000000927. Epub 2023 Jul 6.